These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 4295632)

  • 1. [The intratypical differentiation of strains of the poliovirus group (marker determination)].
    Kuwert E
    Arch Hyg Bakteriol; 1966 Sep; 150(5):447-59. PubMed ID: 4295632
    [No Abstract]   [Full Text] [Related]  

  • 2. [Why intratypical differentiation of poliovirus strains?].
    Thraenhart O; Euwert E
    Dtsch Med Wochenschr; 1972 Aug; 97(32):1192-3. PubMed ID: 4339812
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminum-marker of wild type 1 poliovirus strains.
    Nakao C; Tagaya I; Komatsu T; Kodama H
    Jpn J Microbiol; 1970 Sep; 14(5):405-12. PubMed ID: 4319729
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
    Minor PD; Dunn G; Ramsay ME; Brown D
    J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mutagenic action of proflavine on type 3 poliovirus.
    Pervikov YV; Vorohsilova MK; Chumakov MP; Savinov AP; Yurovetskaya AL
    Acta Virol; 1973 Jul; 17(4):365. PubMed ID: 4148222
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genetic markers of local poliovirus strains isolated during 1966-1969].
    Nikolova M; Tsilka E; Rangelova S; Giurova S
    Izv Mikrobiol Inst (Sofiia); 1971; 22():113-8. PubMed ID: 4340615
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
    Horaud F
    Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
    [No Abstract]   [Full Text] [Related]  

  • 9. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
    Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
    Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dissemination of the vaccine poliomyelitis virus in the families of vaccinated children].
    Szczygielska J; Szmuness W; Radomańska K
    Przegl Epidemiol; 1970; 24(3):329-38. PubMed ID: 4320524
    [No Abstract]   [Full Text] [Related]  

  • 11. Potency testing for killed poliomyelitis vaccine.
    Beale AJ
    Dev Biol Stand; 1981; 47():69-75. PubMed ID: 6262161
    [No Abstract]   [Full Text] [Related]  

  • 12. Investigation of some possibilities of producing type 3 vaccine poliovirus with greater genetic stability. I. Preliminary experiments with passage variants.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV
    Acta Virol; 1968 May; 12(3):193-202. PubMed ID: 4385148
    [No Abstract]   [Full Text] [Related]  

  • 13. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies on safety tests of inactivated poliomyelitis vaccines. V. Pathomorphological changes in the CNS of rhesus monkeys (Macaca rhesus) and long-tailed monkeys (Cercopithecus aethiops) following intracerebral and intralumbar inoculation with inactivated poliovirus types I, II, and 3].
    Unterharnscheidt F; Günther O; Hövel H; Burde K; Heber L
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):150-66. PubMed ID: 4296871
    [No Abstract]   [Full Text] [Related]  

  • 15. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus.
    Chin Med J (Engl); 1980 Sep; 93(9):583-90. PubMed ID: 6253236
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population.
    Herremans T; Kimman TG; Conyn-Van Spaendonck MA; Buisman A; de Melker H; Abbink F; Bijkerk P; Koopmans MP
    Clin Infect Dis; 2002 Apr; 34(8):1067-75. PubMed ID: 11914995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies of genetic markers of poliovirus strains].
    Yamawaki S
    Kumamoto Igakkai Zasshi; 1970 Dec; 44(12):1165-208. PubMed ID: 4325315
    [No Abstract]   [Full Text] [Related]  

  • 18. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The characteristics of poliovirus strains circulating in Ukraine in 1982-1994].
    Zadorozhnaia VI; Bondarenko VI; Siniak LI; Prikhod'ko EF
    Mikrobiol Z; 1998; 60(2):44-9. PubMed ID: 9670753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on safety tests of inactivated poliomyelitis vaccines. IV. Comparative safety tests in rhesus monkeys and long-tailed monkeys (Cercopithecus aethiops)].
    Günther O; Hövel H; von Mettenheim A; Burde K; Heber L; Unterharnscheidt F
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):137-50. PubMed ID: 4296870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.